BRPI0509220A - método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio - Google Patents

método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio

Info

Publication number
BRPI0509220A
BRPI0509220A BRPI0509220-5A BRPI0509220A BRPI0509220A BR PI0509220 A BRPI0509220 A BR PI0509220A BR PI0509220 A BRPI0509220 A BR PI0509220A BR PI0509220 A BRPI0509220 A BR PI0509220A
Authority
BR
Brazil
Prior art keywords
treatment
epithelium
modern
kit
cells
Prior art date
Application number
BRPI0509220-5A
Other languages
English (en)
Inventor
Stephen P Bartels
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0509220(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of BRPI0509220A publication Critical patent/BRPI0509220A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

"MéTODO, FORMULAçãO OFTáLMICA E KIT PARA PARA O TRATAMENTO DE OLHO RESSECADO MODERADO A GRAVE; MéTODO PARA O TRATAMENTO DE OLHO RESSECADO CRÈNICO; E MéTODOS PARA REDUZIR A VERMELHIDãO E A PRODUçãO DE CITOCINAS INFLAMATóRIAS POR CéLULAS NO EPITéLIO". Descrito em modalidades no presente documento está um método de tratamento de olho ressecado moderado a grave em um paciente necessitando do mesmo, sendo que o método compreende administrar etabonato de loteprednol de forma tópica no paciente em um veículo aceitável do ponto de vista oftálmico.
BRPI0509220-5A 2004-03-25 2005-03-24 método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio BRPI0509220A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55616104P 2004-03-25 2004-03-25
PCT/US2005/009761 WO2005094836A2 (en) 2004-03-25 2005-03-24 Use of loteprednol etabonate for the treatment of dry eye

Publications (1)

Publication Number Publication Date
BRPI0509220A true BRPI0509220A (pt) 2007-09-04

Family

ID=34963566

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509220-5A BRPI0509220A (pt) 2004-03-25 2005-03-24 método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio

Country Status (14)

Country Link
US (1) US20050222110A1 (pt)
EP (2) EP2127655A1 (pt)
JP (1) JP2007530573A (pt)
KR (1) KR20070004750A (pt)
CN (1) CN1964719B (pt)
AT (1) ATE441419T1 (pt)
AU (1) AU2005229006B9 (pt)
BR (1) BRPI0509220A (pt)
CA (1) CA2560824A1 (pt)
DE (1) DE602005016392D1 (pt)
ES (1) ES2330762T3 (pt)
MX (1) MXPA06010849A (pt)
TW (1) TW200602030A (pt)
WO (1) WO2005094836A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
CN101317847B (zh) * 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
US20090239836A1 (en) * 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis
WO2013133980A1 (en) * 2012-03-05 2013-09-12 Bausch & Lomb Incorporated Nitroxy derivatives of soft steroids
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN106279325A (zh) * 2015-05-27 2017-01-04 天津金耀集团有限公司 一种依碳氯替泼诺新晶型及其制备方法
CN106279324A (zh) * 2015-05-27 2017-01-04 天津金耀集团有限公司 依碳氯替泼诺一水合物及其晶型与制备方法
CN106892952A (zh) * 2015-12-21 2017-06-27 天津金耀集团有限公司 一种依碳氯替泼诺新晶型及其制备方法
CN106892953A (zh) * 2015-12-21 2017-06-27 天津金耀集团有限公司 依碳氯替泼诺一水合物及其晶型与制备方法
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018212846A1 (en) * 2017-05-19 2018-11-22 Ocugen, Inc. Ophthalmic compositions and methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US104A (en) 1836-12-10 Revolving hokse-rake
US5075A (en) 1847-04-17 Improvement in cultivators
US4710495A (en) 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US6610675B1 (en) 1980-07-10 2003-08-26 Nicholas S. Bodor Inactive metabolite approach to soft drug design
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
EP0459148B1 (en) 1990-05-29 1996-01-03 Ocular Research Of Boston Inc. Dry eye treatment composition
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6096052A (en) * 1998-07-08 2000-08-01 Ovion, Inc. Occluding device and method of use
US7073504B2 (en) * 1996-12-18 2006-07-11 Ams Research Corporation Contraceptive system and method of use
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
DE19947234A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
EP1392322A1 (en) 2001-05-21 2004-03-03 Alcon, Inc. Method of treating dry eye disorders
PL369960A1 (en) * 2001-10-11 2005-05-02 Alcon, Inc. Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue
MXPA04008171A (es) * 2002-02-22 2004-11-26 Pharmacia Corp Formulacion oftalmica con sistema de goma.
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
AU2003301129A1 (en) * 2002-12-20 2004-07-22 Control Delivery Systems, Inc. Steroid compositions for intraocular use
WO2004073748A1 (ja) * 2003-02-20 2004-09-02 Senju Pharmaceutical Co., Ltd. 水性懸濁液剤
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye

Also Published As

Publication number Publication date
WO2005094836A3 (en) 2006-01-26
TW200602030A (en) 2006-01-16
AU2005229006B2 (en) 2011-01-20
HK1102551A1 (en) 2007-11-30
CN1964719A (zh) 2007-05-16
EP1744759A2 (en) 2007-01-24
EP2127655A1 (en) 2009-12-02
DE602005016392D1 (de) 2009-10-15
US20050222110A1 (en) 2005-10-06
KR20070004750A (ko) 2007-01-09
CA2560824A1 (en) 2005-10-13
JP2007530573A (ja) 2007-11-01
EP1744759B1 (en) 2009-09-02
WO2005094836A2 (en) 2005-10-13
AU2005229006A1 (en) 2005-10-13
ATE441419T1 (de) 2009-09-15
MXPA06010849A (es) 2007-03-08
AU2005229006B9 (en) 2011-05-19
CN1964719B (zh) 2010-05-05
ES2330762T3 (es) 2009-12-15

Similar Documents

Publication Publication Date Title
BRPI0509220A (pt) método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio
CA2690111A1 (en) Anthelmintic combination
WO2005046618A3 (en) Methods of treating eczema
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
WO2021126320A9 (en) Treatment of amyotrophic lateral sclerosis and related disorders
AR034619A1 (es) Formulaciones de olopatadine para administracion topica
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
NZ701559A (en) Compositions comprising povidone-iodine
WO2003088906A3 (en) Methods of simultaneously treating ocular rosacea and acne rosacea
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
CY1109763T1 (el) Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
CR8453A (es) Metodo para el tratamiento de trastornos oftalmicos
WO2010004435A3 (en) Ph specific solutions of sodium mycophenolic acid for the treatment of eye disorders
EE05315B1 (et) Dapoksetiini v?i selle farmatseutiliselt vastuv?etava soola kasutamine ravimi valmistamiseks, mis on ette n„htud imetajal esineva seksuaalse funktsioonih„ire ravimiseks v?i m?jutamiseks
EA200700074A1 (ru) Способ повышения скорости заживления повреждения ( варианты ), устройство доставки перекиси водорода и композиция для лечения повреждений у млекопитающих
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
AR033207A1 (es) Metodo de tratamiento de desordenes inflamatorios oculares y de desordenes relacionados con angiogenesis del segmento posterior del ojo usando un derivado amida de flurbiprofen o ketorolac
EA201170970A1 (ru) Применение деферипрона для лечения и предупреждения заболеваний глаз, связанных с железом
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
WO2023019095A3 (en) Momelotinib combination therapy
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B11T Dismissal of application maintained [chapter 11.20 patent gazette]